BIOMAT Database Logo BIOMAT Database Logo

Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. 1998

Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
First Department of Internal Medicine, Showa University, Tokyo, Japan.

BACKGROUND Rush immunotherapy (RIT) has been shown to be effective in allergic asthma. OBJECTIVE We investigated the mechanisms of RIT on the basis of cytokine production by T-cell lines and airway inflammation and responsiveness. METHODS Subjects were 8 patients with house dust mite-allergic asthma treated with dust mite extract RIT for 6 months and 6 RIT-untreated control patients. IL-5 production by Dermatophagoides farinae -specific T-cell lines, eosinophil percentages, and eosinophil cationic protein (ECP) in induced sputum and airway responsiveness to allergen and histamine were evaluated before and after treatment. Changes in eosinophil percentages and ECP in induced sputum and responsiveness to histamine 24 hours after allergen inhalation were also studied. RESULTS After 6 months of RIT, percentages of total eosinophils (43. 0% +/- 6.90% to 16.8% +/- 2.48%; P <.01), percentages of EG2(+ ) eosinophils (32.6% +/- 6.39% to 19.7% +/- 4.68%; P <.01) and ECP (362.7 +/- 125.3 ng/mL to 26.2 +/- 5.15 ng/mL; P <.05) decreased in induced sputum, and IL-5 production by T-cell lines decreased (617 +/- 93.2 pg/mL to 200.0 +/- 34.1 pg/mL; P <.01). RIT decreased both early- and late-phase bronchoconstriction (early phase: 33.2% +/- 3. 46% to 25.4% +/- 1.42%; P <.03; late phase: 16.2% +/- 3.52% to 6.2% +/- 1.96%; P <.03) and suppressed increases in the percentages of total (61.8% +/- 4.89% to 42.0% +/- 4.67%; P <.01) and EG2-positive eosinophils (55.54% +/- 7.21% to 36.5% +/- 6.43%; P <.01) and ECP (685.6 +/- 217.0 ng/mL to 85.4 +/- 23.4 ng/mL; P <.05) in induced sputum after allergen inhalation. RIT also decreased airway responsiveness to dust mite (1:303.7 +/- 123.7 wt/vol to 1:65.0 +/- 13.2 wt/vol; P <.03) and to histamine before (397.1 +/- 206.9 microgra/mL to 1391.3 +/- 283.3 microgram/mL; P <.03) and after allergen inhalation (139.2 +/- 36.5 microgram/mL to 629.1 +/- 196.3 microgram/mL; P <.03). CONCLUSIONS RIT decreases airway inflammation and airway hyperresponsiveness before and after bronchial provocation with allergen, possibly by inhibiting both allergen-specific T-cell- and mast cell-dependent pathways. RIT is an effective antiinflammatory treatment in allergic asthma.

UI MeSH Term Description Entries
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001985 Bronchial Provocation Tests Tests involving inhalation of allergens (nebulized or in dust form), nebulized pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma. Allergen Bronchial Provocation Tests,Allergen Challenge, Endobronchial,Antigen Bronchial Provocation Tests,Bronchial Allergen Challenge,Bronchial Challenge Tests,Inhalation Provocation Tests,Provocation Tests, Bronchial,Endobronchial Challenge Tests,Allergen Challenge, Bronchial,Allergen Challenges, Bronchial,Allergen Challenges, Endobronchial,Bronchial Allergen Challenges,Bronchial Challenge Test,Bronchial Provocation Test,Challenge Test, Bronchial,Challenge Test, Endobronchial,Challenge Tests, Bronchial,Challenge Tests, Endobronchial,Challenge, Bronchial Allergen,Challenge, Endobronchial Allergen,Challenges, Bronchial Allergen,Challenges, Endobronchial Allergen,Endobronchial Allergen Challenge,Endobronchial Allergen Challenges,Endobronchial Challenge Test,Inhalation Provocation Test,Provocation Test, Bronchial,Provocation Test, Inhalation,Provocation Tests, Inhalation,Test, Bronchial Challenge,Test, Bronchial Provocation,Test, Endobronchial Challenge,Test, Inhalation Provocation,Tests, Bronchial Challenge,Tests, Bronchial Provocation,Tests, Endobronchial Challenge,Tests, Inhalation Provocation
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D003888 Desensitization, Immunologic Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity. Allergen Immunotherapy,Allergy Shots,Hyposensitization Therapy,Immunotherapy, Allergen,Venom Immunotherapy,Immunologic Desensitization,Therapy, Hyposensitization,Allergen Immunotherapies,Allergy Shot,Desensitizations, Immunologic,Hyposensitization Therapies,Immunologic Desensitizations,Immunotherapy, Venom,Shot, Allergy,Venom Immunotherapies
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
Airway eosinophilic inflammation and bronchial hyperresponsiveness after allergen inhalation challenge in asthma.
January 1998, Lung,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
Remodeling and airway hyperresponsiveness but not cellular inflammation persist after allergen challenge in asthma.
May 2007, American journal of respiratory and critical care medicine,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
[Airway inflammation and hyperresponsiveness in asthma].
May 2015, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
The effect of segmental bronchoprovocation with allergen on airway lymphocyte function.
November 1997, American journal of respiratory and critical care medicine,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients.
September 2002, The Journal of asthma : official journal of the Association for the Care of Asthma,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
Asthma, inflammation, and airway hyperresponsiveness in children.
June 1993, Current opinion in pediatrics,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
Thioredoxin suppresses airway hyperresponsiveness and airway inflammation in asthma.
September 2005, Biochemical and biophysical research communications,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
[Effect of heat shock factor 1 on airway hyperresponsiveness and airway inflammation in mice with allergic asthma].
February 2017, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
Airway hyperresponsiveness: relation to asthma and inflammation?
November 1993, Thorax,
Y Kohno, and K Minoguchi, and N Oda, and T Yokoe, and N Yamashita, and T Sakane, and M Adachi
Bronchial hyperresponsiveness, atopy, airway inflammation, and asthma.
May 1998, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,
Copied contents to your clipboard!